Actionable news
All posts from Actionable news
Actionable news in KERX: Keryx Biopharmaceuticals, Inc.,

Stock Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia® (ferric citrate) and Second Quarter 2016 Financial Results

Keryx Biopharmaceuticals (NASDAQ:KERX) announced that an interruption in the supply of Auryxia® (ferric citrate) tablets is imminent due to a production-related issue converting active pharmaceutical ingredient (API) to finished drug product. Keryx expects to make Auryxia available to patients when supply of Auryxia is back to adequate levels, which Keryx anticipates will be during the fourth quarter of 2016.

“We take our responsibility to patients and the treating community very seriously and recognize the impact this interruption of supply will cause for patients and their healthcare providers,” said Greg Madison, chief executive officer of Keryx Biopharmaceuticals. “Our field-based...